

Supplementary Table 1. Characteristics of CTP-BADX/NS patients

Patient	Gender	Age	preoperative_ACTH	Hyperpigmentation	ACTH at progression	Relative Δ _ACTH	Max_tumor_size-progression	Oculomotorius	Abducens	Opticus	Central hypothyroidism	Central hypogonadism	GHD	DI	Surgery	Radiotherapy	Medical therapy	Control of tumor progression at last follow-up	Death
1	F	27	63	yes	689	993	6	No	No	No	No	No	No	No	no	no	no	yes	no
2	F	67	64	no	227	256	15	No	No	No	Yes	Yes	No	No	no	SRS	no	yes	no
3	F	52	49	yes	4268	8610	10	No	No	No	No	No	No	No	yes	FRT	no	yes	no
4	F	40	363	yes	n/a	n/a	n/a	No	No	No	No	No	No	No	yes	FRT	no	yes	no
5	F	30	95	n/a	1545	1526	13	No	No	No	No	No	No	No	yes	FRT	no	yes	no
6	F	54	281	n/a	568	102	22	No	No	Yes	No	No	No	No	no	FRT	temozolomide + cabergoline	no	yes
7	F	18	n/a	n/a	7727	n/a	7	No	No	No	Yes	No	No	No	yes	no	no	yes	no
8	M	32	39	yes	19545	50005	25	No	No	Yes	No	Yes	Yes	No	yes	FRT	no	yes	no
9	M	64	231	no	2000	765	54	Yes	Yes	No	No	Yes	No	No	no	no	temozolomide	no	no
10	F	57	41	n/a	543	1224	12	No	No	No	No	No	No	No	no	SRS	no	yes	no
11	M	62	98	no	407	315	24	No	No	No	Yes	Yes	No	No	yes	SRS	no	no	no

12	F	63	11	no	242	1120	10	Yes	No	No	No	No	No	No	no	no	unspecified	yes	no
13	M	n/a	338	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	no	no	no	no	no
14	F	66	18	yes	1650	9016	9	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	no	yes
15	F	n/a	76	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	no	no	no	no	no
16	F	n/a	29.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	no	yes
17	M	69	169	yes	770	355	34	No	No	Yes	Yes	Yes	Yes	No	no	no	temozolomide	no	yes
18	M	76	103	yes	248	140	n/a	No	No	Yes	Yes	Yes	Yes	Yes	yes	no	temozolomide+bevacizumab	no	yes
19	F	54	137	n/a	709	417	28	No	No	Yes	Yes	Yes	Yes	Yes	no	no	temozolomide	no	yes
20	F	47	49	yes	878	1691	n/a	No	No	No	No	No	No	No	no	no	no	yes	no
21	F	27	137	yes	2199	1505	7	No	No	No	No	No	No	No	no	SRS	no	yes	no
22	F	47	31	yes	1250	3932	7,5	No	No	No	No	No	No	No	no	yes, unspecified	no	no	no
23	F	60	93	yes	1252	1246	6	No	No	No	No	No	No	No	no	SRS	no	yes	no
24	F	48	96	yes	1099	1044	5,9	No	No	No	No	No	No	No	no	yes, unspecified	no	yes	no
25	M	48	n/a	yes	1932	n/a	20	Yes	Yes	Yes	Yes	Yes	Yes	No	yes	no	no	yes	no
26	F	39	34	yes	806	2270	13	No	No	No	No	No	Yes	No	no	no	no	no	no
27	F	n/a	22	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	no	no	pasireotide	no	no
28	F	45	81	yes	1331	1537	n/a	Yes	Yes	No	Yes	Yes	No	No	no	no	no	yes	no
29	F	60	65	yes	1263	1843	22	No	No	Yes	Yes	Yes	No	No	yes	SRS	temozolomide+pasireotide	no	yes
30	M	47	636	yes	1445	127	40	No	No	No	Yes	Yes	No	No	no	FRT	no	no	yes
31	F	32	52	yes	4681	8901	18	No	No	No	No	No	No	No	no	yes, unspecified	no	no	no
32	F	33	234	yes	1827	680	33	No	No	No	No	No	No	No	no	FRT	no	yes	no
33	F	31	n/a	yes	518	n/a	7,7	No	No	No	No	No	No	No	no	FRT	pasireotide	yes	no

N/a, not available; GHD, growth hormone deficiency; DI, diabetes insipidus; ACTH values are expressed as pg/ml; FRT, fractionated radiation therapy; SRS, stereotactic radiosurgery; relative ACTH delta (Δ) was calculated using the formula: [(ACTH at progression -preoperative ACTH)*100]/preoperative ACTH

